Mr. Andral graduated from Ecole Centrale de Paris in 1971 asan engineer in arts and Manufactures and has a MBA of INSEAD in Fontainebleau.

Mr. Andral received the President’s award of GE in 2005.

Dr Barer joined the Celanese Research Company in 1974 and formed the Biotechnology group that was subsequently spun out to form Celgene.

Dr. Barer holds numerous awards including the “Dream & Promise Award” (Children’s Brain Tumor Foundation) “Odyssey Award” (Center for Medicine in the Public Interest), the “Corporate Vision Award” (Gilda’s Club), the “Sparkle of Hope Award” (Community Hope), “Master Entrepreneur Award” (Ernst & Young), “The Hall of Distinguished Alumni Award” (Rutgers University Alumni Federation), “Dr. Sol J. Barer Award for Vision, Innovation and Leadership” (BioNJ), “Science and Technology Industry Medal” (R&D Council of NJ), “Rutgers University Graduate School Annual Distinguished Alumnus Award”, “Winthrop-Sears Medal” (The Chemists Club and the Chemical Heritage Foundation), and “Albert Einstein Award in Life Sciences” (Global Capital Associates and Jerusalem Fund, Israel), “DART/NYU Biotechnology Achievement Award in Applied Biotechnology” (Biotechnology Study Center of the New York University School of Medicine).

Dr. Barer is also is on the Board of Directors of Amicus Therapeutics, serves on the Board of Trustees of BioNJ and is on the Board of the Brooklyn College Foundation and on the Board of Trustees of Rutgers – The State University of New Jersey. He has previously served as a Commissioner of the New Jersey Commission on Science and Technology.

Dr. Barer received a PhD in Organic Chemistry from Rutgers University and BS from Brooklyn College.

Ms. Bartiromo joined CNBC in 1993 after five years as a producer and assignment editor with CNN Business News. In 1995, Ms. Bartiromo became the first journalist to report live from the New York Stock Exchange on a daily basis for Squawk Box. She reported from the NYSE for 10 years.

In May 2008, Ms. Bartiromo received a Gracie Award in the category of Outstanding Documentary for her documentary "Greenspan: Power, Money & the American Dream."

Ms. Bartiromo writes a weekly column in BusinessWeek, "FaceTime with Maria Bartiromo," as well as a weekly column in Milano Finanza. Ms. Bartiromo writes a weekly column in BusinessWeek, "FaceTime with Maria Bartiromo," as well as a weekly column in Milano Finanza.

In addition to being a member of the Board of Trustees of New York University, Bartiromo is on the Board of Directors of the New York City Ballet, the Girl Scout Council of Greater New York; as well as PENCIL, Public Education Needs Civic Involvement and Leadership, which is a non profit group focusing on improving New York high schools. She also is a Young Global Leader of the World Economic Forum, a member of The Wharton Leadership Advisory Board and a member of the Columbus Citizens Foundation.

Ms. Bartiromo graduated from New York University, where she majored in journalism and minored in economics.

David began his career in 1975 at Merck, where he started as a sales representative in the U.S. Division and later worked in sales and marketing management in the US and International divisions. He joined AstraMerck in 1992 and helped to build the joint venture into a multi-billion dollar business in the U.S. which was then merged to form AstraZeneca in 1999.

He is an alumnus of Gettysburg College where he studied Business Administration.

In addition to his role as Executive Director of AstraZeneca PLC he is also:

• Chairman-elect of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• Member of the Executive Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA)
• Member of the European Roundtable of Industrialists
• Member of the National Institute of Health Roundtable on Evidence Based Medicine
• Commissioner of the UK Commission for Employment and Skills
• Past Chairman of the Board of the Southeastern Pennsylvania Chapter of the American Heart Association
• Honorary Board member of the US CEO Roundtable on Cancer

Author of two books of what he calls “comic sociology”— descriptions of how we live and “the water we swim in” that are as witty and entertaining as they are revealing and insightful: Bobos in Paradise and On Paradise Drive. Bobos in Paradise was a New York Times bestseller.

David Brooks has worked at The Weekly Standard, joining the magazine at its inception and serving as senior editor. He has been a contributing editor at Newsweek and the Atlantic Monthly. He worked at The Wall Street Journal for nine years in a range of positions, including op-ed editor. He has written for The New Yorker, The New York Times Magazine, Forbes, The Washington Post and many other periodicals.

Dr. Buckley previously worked as a consultant at McKinsey and Company where he advised a variety of companies including health insurance and pharmaceutical companies.

Prior to joining McKinsey and Company, Dr. Buckley was the first National Center for Health Statistics (NCHS)/AcademyHealth fellow, where he completed his dissertation research.

Before graduate school, Dr. Buckley worked in a range of fields including IT consulting, operations and logistics management and served as a live-in assistant for mentally handicapped adults in L’Arche communities in both Canada and Germany.

Dr. Buckley received is BA in 1991 in Mathematics from the University of Pennsylvania, his MA in 2001 and his PhD in 2004 in Applied Economics from the Wharton School of Business, University of Pennsylvania.

Mr. Carroll has also served as senior vice president of RealMed, a venture-backed company based in Indianapolis, which created the first real-time health claims adjudication system. Earlier in his career, he practiced law with a large private law firm in New York and negotiated complex technology transactions for General Electric Company.

His education includes a J.D. degree from Syracuse University College of Law. He also holds a bachelor's from Syracuse University and a masters of public administration degree from the Maxwell School of Syracuse, where he is a member of the Board of Advisors. He is also a member of the Board of Directors for Lilly Ventures and Lilly Asian Ventures portfolio companies including Citic Pharmaceuticals, Novast Holdings, Hydra Biosciences, InnoCentive and GlobeImmune, and is chairman of the advisory board for the Indiana Future Fund.

Previously Mr. Clark held the position of President of the Merck Manufacturing Division, with responsibility for Merck's global network of manufacturing operations, information services and operational excellence organizations worldwide.

In a career spanning more than 36 years with Merck, Mr. Clark has held a broad range of senior management positions within the company's manufacturing organization. Mr. Clark joined Merck in 1972 as a Quality Control Inspector, and he progressed through a series of increasingly responsible roles in the areas of production, new products planning, industrial engineering and management engineering, becoming Vice President, Materials Management and Management Engineering in 1991.

In 1993, Mr. Clark was appointed Vice President, Procurement and Materials Management. He became Vice President of North American Operations for the Merck Manufacturing Division in 1994 and Senior Vice President in 1996. In 1997, he was appointed Senior Vice President of Quality and Commercial Affairs. Later that year, Mr. Clark joined the Merck-Medco Managed Care subsidiary as Executive Vice President and Chief Operating Officer. He later served as Chairman, President and Chief Executive Officer of the newly named Medco Health Solutions, overseeing plans to prepare that organization to become a publicly traded company. He returned to the Merck Manufacturing Division as President in June 2003.

From 2008 to 2009 he served as board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country's leading pharmaceutical research and biotechnology companies.

Mr. Clark earned his bachelor's degree in Liberal Arts from Washington & Jefferson College, and his M.B.A. from American University. He served as a Lieutenant in the U.S. Army from 1970 to 1972 before joining Merck.

Mr. Davis joined the Johnson & Johnson Family of Companies in 1984. He moved through line leadership positions of increasing responsibility in the organization in the U.S., Europe and Asia and then to Company Group Chairman for Diagnostics (worldwide) in 2003, before assuming his current role in January, 2008.

He is currently a member of the Industrial Advisory Board of Cleveland Clinic.

Mr. Davis received a Bachelor of Science degree from the State University of New York and a Master of Science degree from Rensselaer Polytechnic Institute.

Dr. Doroshow received his bachelor=s degree, magna cum laude, from Harvard College in 1969 and his medical degree alpha omega alpha from Harvard Medical School in 1973. After completing an internship and residency in Internal Medicine at the Massachusetts General Hospital in Boston, he spent three years (1975-78) performing his fellowship in Medical Oncology on the Medicine and Clinical Pharmacology Branches of the NCI.

David has been a Contributing Editor and columnist for Conde Nast Portfolio, and a Contributing Editor for Wired and Discover; he has been a longtime commentator for NPR’s “Morning Edition”, and a special correspondent and producer for ABC’s Nightline and 20/20. He has been a correspondent for NOVA’s ScienceNow!, and a producer for Discovery Television. He has written for Harper’s, Atlantic Monthly, Smithsonian, Outside, The Telegraph, The Guardian, The Washington Post Book World, The San Francisco Chronicle, and The New York Times, among others.

Additionally, Epstein is responsible for leading Novartis Molecular Diagnostics, a new business launched in December 2008 to recognize the growing role of diagnostics in improving healthcare utilization worldwide. He is a member of Novartis AG’s Pharma Committee, a member of the Pharma Executive Committee (PEC) and a member of the Executive Council of Novartis (ECN).

Epstein has held a series of positions of increasing responsibility since joining the company as a new product manager with Sandoz in 1989. Epstein most recently served as Chief Executive Officer, Novartis Specialty Medicines, overseeing the global Ophthalmics and Transplantation & Immunology Business Units in addition to his responsibilities leading Novartis Oncology. He previously served as Chief Operating Officer of Novartis Pharmaceuticals Corporation in the U.S and has held several positions in marketing and general management.

During the planning process that resulted in the 1996 merger of Ciba-Geigy Ltd. and Sandoz Ltd., Epstein co-chaired the U.S. and Canadian Pharma Steering Committees as the Integration Officer, North America. In January 1997, he was promoted to Vice President, Marketing and Sales, Specialty Business Sector, responsible for U.S. business units focused on Oncology and Transplant/Immunology/Tissue Engineering. Prior to joining the company, he was an associate in the Strategy Practice of consulting firm Booz, Allen and Hamilton.

Epstein holds a BS degree in Pharmacy with high honors from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.

Gaynor received a bachelor of science degree in biology from Texas Tech University and received a doctor of medicine degree from the University of Texas Southwestern Medical School. He served his internship and residency in internal medicine from at Parkland Memorial Hospital in Dallas, Texas. He completed a fellowship in hematology-oncology at the University of California at Los Angeles (UCLA) School of Medicine and then served on it’s faculty. He received board certification in internal medicine, hematology and medical oncology.

Prior to joining Lilly, Gaynor was a Professor of Medicine and Microbiology at the University of Texas Southwestern Medical Center (UTSW) in Dallas and held several important leadership positions. He was Chief of the Division of Hematology and Oncology at UTSW and Director of the Harold C. Simmons Comprehensive Cancer Center there in addition to his work as the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology. He served on numerous NIH advisory committees and was elected to both the American Society of Clinical Investigation and Association of American Physicians.

Gaynor is on the editorial board of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He serves on the board of the Damon Runyon Cancer Research Foundation and the Walther Cancer Institute and on several committees for the American Association of Cancer Research and other leading cancer organizations.

Prior to joining Johnson & Johnson, he was the founding Director of The Cancer Institute of New Jersey and Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School from January 1993 to March 2007. Under Dr. Hait's leadership, The Cancer Institute of New Jersey was successful in obtaining cancer center designation from the National Cancer Institute in 1996 and received the National Cancer Institute's highest designation of Comprehensive Cancer Center in 2002.

After earning his B.A. from the University of Pennsylvania, Dr. Hait received his M.D. and Ph.D. (Pharmacology) cum laude from the Medical College of Pennsylvania, where he was elected to Alpha Omega Alpha. He joined the Yale University School of Medicine faculty in 1984 and was quickly promoted to Associate Professor of Medicine and Pharmacology. Dr. Hait served as Associate Director of the Yale University Comprehensive Cancer Center and Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit at the Yale University School of Medicine. He was appointed Chief of Medical Oncology at the Yale University School of Medicine in 1988. Dr. Hait is Board Certified in Internal Medicine and Medical Oncology.

Dr. Hait served as President of the American Cancer Society, Middlesex Unit in 1998 and is currently a member of their Board. He is a member of the Medical Advisory Board of both the New Jersey Breast Cancer Coalition and Susan G. Komen Foundation and is an active member on Scientific Advisory Boards of several universities. He served on various committees for the American Association for Cancer Research (Chair, Clinical Cancer Research Committee), American Society of Clinical Oncology, the Association of American Cancer Institutes (Board of Directors), and the National Cancer Institute Board of Scientific Advisors. Dr. Hait served as President of the American Association for Cancer Research from 2007 - 2008.

Dr. Hamburg graduated from Harvard Medical School, and completed her residency in internal medicine at what is now New York Presbyterian Hospital-Weill Cornell Medical Center, one of the top-ten hospitals in the nation. She conducted research on neuroscience at Rockefeller University in New York, studied neuropharmacology at the National Institute of Mental Health on the NIH campus in Bethesda, and later focused on AIDS research as Assistant Director of the National Institute of Allergy and Infectious Diseases.

In 1990, Dr. Hamburg joined the New York City Department of Health and Mental Hygiene as Deputy Health Commissioner, and within a year was promoted to Commissioner, a position she held until 1997. During her tenure she was widely praised for her initiatives, decisive leadership, and significant public health measures she carried out despite severe budget constraints and while holding academic positions at Columbia University School of Public Health and Cornell University Medical College.

Dr. Hamburg’s accomplishments as New York’s top public health official included improved services for women and children, a needle-exchange program to reduce the spread of HIV, and the initiation of the first public health bio-terrorism defense program in the nation. Her most celebrated achievement, however, was curbing the spread of tuberculosis. In the 1990s, TB resurged as a major public health threat, largely because many patients did not complete the full course of the treatment and the disease became resistant to standard drugs. Dr. Hamburg confronted the problem by sending health care workers to patients’ homes and taking other steps to make sure they completed the drug regimen. Thanks to this program, in a 5 year span, the TB rate in New York City fell by 46% overall, and 86% for the most drugresistant strains. Dr. Hamburg’s innovative approach has become a model for health departments world-wide.

In 1994, Dr. Hamburg was elected to the membership in the Institute of Medicine, one of the youngest persons to be so honored. three years later, at the request of President Clinton, she accepted the position of Assistant Secretary for Policy and Evaluation in the U.S. Department of Health and Human Services (HHS).

In 2001, Dr. Hamburg became Vice President for Biological Programs at the Nuclear Threat Initiative, a foundation dedicated to reducing the threat to public safety from nuclear, chemical, and biological weapons. In that position, she has advocated broad reforms in public health infrastructure and policy, from local health departments to the national agency, in order to meet the dangers of modern bioterrorism as well as the threats of naturally occurring infectious diseases such as pandemic flu. Since 2005, Dr. Hamburg has served as the Initiative’s Senior Scientist. President Barack Obama nominated her for the FDA Commissioner on March 25, 2009.

Upon Dr. Hamburg’s confirmation by the U.S. Senate, HHS Secretary Kathleen Sebelius has praised her as “an inspiring public health leader with broad experience in infectious disease, bioterrorism, and health policy”, and added that “Personally, I have been impressed by the calm and confidence Dr. Hamburg has shown in the face of a wide variety of challenges.”

Prior to joining Schering-Plough in April 2003 and assuming his current position, Hassan was chairman and chief executive officer of Pharmacia Corporation. He joined the former Pharmacia & Upjohn in May 1997 as chief executive officer and was elected to the Board of Directors. In February 2001, Hassan was named chairman of the Board of Pharmacia, the company created through the merger of the former Monsanto and Pharmacia & Upjohn companies.

Previously, Hassan was executive vice president of Wyeth, formerly known as American Home Products, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth’s Board of Directors in 1995. Earlier in his career, Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its U.S. pharmaceuticals business.

Hassan received a B.S. degree in chemical engineering from the Imperial College of Science and Technology at the University of London and an M.B.A. from Harvard Business School.

Hassan is the past chairman of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and is the immediate past chairman of the HealthCare Institute of New Jersey. He is currently president of the International Federation of Pharmaceutical Manufacturers Associations. In addition, he serves on the Board of Directors of Avon Products, Inc.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough’s vision is to “Earn Trust, Every Day” with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

Before joining Forbes, Mr. Langreth was a Staff Reporter at the Wall Street Journal from 1995 to 2000 and an Associate Editor at Popular Science from 1992 to 1994. He is the recipient of several journalism awards, including a 1993 Evert Clark Award for Best Science Writing and a 1998 Council for the Advancement of Science Writing (CASW) Award. He was the co-recipient of a 1997 Polk Award.

Mr. Langreth graduated from Yale University in 1990 with a BA degree in Physics and Philosophy.